Portola receives CRL from FDA for AndexXa BLA
Portola Pharmaceuticals Inc. recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) submitted for AndexXa (andexanet alf Read More »